SAN DIEGO, May 03, 2022 (GLOBE NEWSWIRE) -- Progenity, Inc. (NASDAQ:PROG) today announced that it will report first quarter ended March 31, 2022 financial results on Tuesday, May 10, 2022 after the close of financial markets. Progenity's management will host a webcast and conference call at 4:30 p.m. Eastern time / 1:30 p.m. Pacific time that day to discuss the financial results and provide a corporate update.

As previously announced, Progenity is changing to Biora Therapeutics. Biora will focus on its pipeline of targeted and systemic oral biotherapeutics. The legal name change was completed on April 26, 2022, and the brand launch for Biora Therapeutics™ will coincide with the earnings call on May 10. The company's NASDAQ ticker symbol will also change from "PROG" to "BIOR" on that day. No action is needed from current stockholders. The company's common stock will continue to be listed on NASDAQ and the CUSIP will not change.

The live call on May 10 may be accessed by dialing 1-800-926-4402 (domestic) or 1-416-641-6700 (international) and entering the conference code: 22018599. A live webcast will be available via the Investor Relations section of the company website at bioratherapeutics.com, with a replay available online for 60 days following the call.

About Progenity

Progenity, Inc. is a biotechnology company innovating in the fields of gastrointestinal health and oral biotherapeutics and is developing a suite of investigational ingestible devices designed to provide precise drug delivery solutions and diagnostic sampling. Progenity will become Biora Therapeutics on May 10, 2022.

For more information visit www.progenity.com, or follow the company on LinkedIn or Twitter.

For updates about Biora Therapeutics, please follow on LinkedIn or Twitter.

Investor Contact

Chuck Padala

Managing Director, LifeSci Advisors

ir@progenity.com

(646) 627-8390

Media Contact

Kristin Schaeffer

CG Life

media@progenity.com

(858) 457-2436

Progenity to Report First Quarter Financial Results and Provide Corporate Update as Biora Therapeutics, Inc.